Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma

The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy.

Researchers will review existing clinical, pathologic, and follow-up data from 414 patients treated at three medical centers between 2019 and 2025. The study will assess whether routinely available clinicopathologic factors can provide prognostic information beyond postoperative pathologic staging.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Esophageal Squamous Cell Carcinoma Carcinoma Carcinoma, Squamous Cell Digestive System Diseases Digestive System Neoplasms Esophageal Diseases Esophageal Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Head and Neck Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Neoplasms, Squamous Cell

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

West China Hospital, Sichuan University, Chengdu, Sichuan, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18 to 80 years Histologically confirmed esophageal squamous cell carcinoma Received at least 1 cycle of neoadjuvant chemoimmunotherapy before surgery Underwent subsequent esophagectomy

Exclusion criteria

History of other malignancies Preoperative antitumor therapy other than neoadjuvant chemoimmunotherapy Incomplete clinicopathologic or follow-up data

Treatment and study plan

Primary outcomes

Overall Survival (OS)

Time frame: From the date of esophagectomy to death or last follow-up, up to 73 months.

Overall survival is defined as the interval from the date of esophagectomy to death from any cause. Participants alive at last contact are censored on the date of last follow-up.

Sponsors and collaborators

Lead sponsor

Sichuan University

Other

Registry information

Official study title

Development and Internal Validation of a Clinicopathologic Prognostic Model for Overall Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoimmunotherapy and Esophagectomy: A Multicenter Retrospective Cohort Study

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2026
First posted: Mar 23, 2026
Registry last updated: Aug 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed